'HIV-ending' drug could be made for just $25 per patient a year, say researchers

By The Guardian | 1 week ago

Campaigners are pushing for Gilead to make lenacapavir, a potential gamechanger in HIV prevention, affordable and accessible worldwide. Despite estimated production costs of $25 a year, the drug's price remains uncertain, raising concerns about global access and affordability.

Did you find this insightful?